# Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis

> **NCT02473406** · PHASE4 · COMPLETED · sponsor: **Weiqin Li** · enrollment: 508 (actual)

## Conditions studied

- Pancreatitis, Acute Necrotizing

## Interventions

- **DRUG:** Thymosin Alpha 1
- **DRUG:** normal saline

## Key facts

- **NCT ID:** NCT02473406
- **Lead sponsor:** Weiqin Li
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-27
- **Primary completion:** 2020-12-24
- **Final completion:** 2021-03-24
- **Target enrollment:** 508 (ACTUAL)
- **Last updated:** 2021-04-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02473406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02473406, "Thymosin Alpha 1 in the Prevention of Pancreatic Infection Following Acute Necrotizing Pancreatitis". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02473406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*